Our clinical-stage monoclonal antibody, Xentuzumab – formerly designated BI 836845 – represents a significant effort by Astellas Pharma targeting PD-1. Its progression initially focused on solid tumor indications, https://dawudfdfm039313.aboutyoublog.com/54125057/xentuzumab-a-deep-analysis-into-bi-836845-and-its-evolution